{"Enzalutamide,": [0], "an": [1], "androgen-receptor": [2], "inhibitor,": [3], "has": [4], "been": [5], "associated": [6, 247], "with": [7, 13, 27, 37, 164, 248, 260, 285], "improved": [8], "overall": [9, 72, 137, 253], "survival": [10, 34, 79, 138, 172, 186, 254], "in": [11, 35, 110, 117, 148, 158, 169, 183, 205, 210, 224, 230, 233, 239, 242, 258], "men": [12, 36, 97, 259], "castration-resistant": [14], "prostate": [15, 40, 263], "cancer.": [16], "It": [17], "is": [18], "not": [19], "known": [20], "whether": [21], "adding": [22], "enzalutamide": [23, 58, 112, 150, 165, 207, 226, 235, 269], "to": [24, 51, 129, 199], "testosterone": [25, 53, 266], "suppression,": [26], "or": [28, 59], "without": [29], "early": [30, 286], "docetaxel,": [31], "will": [32], "improve": [33], "metastatic,": [38, 261], "hormone-sensitive": [39, 262], "cancer.In": [41], "this": [42], "open-label,": [43], "randomized,": [44], "phase": [45], "3": [46, 140], "trial,": [47], "we": [48], "assigned": [49], "patients": [50, 232, 241], "receive": [52], "suppression": [54], "plus": [55], "either": [56], "open-label": [57], "a": [60, 272], "standard": [61, 256], "nonsteroidal": [62], "antiandrogen": [63], "therapy": [64], "(standard-care": [65], "group).": [66], "The": [67, 268], "primary": [68], "end": [69, 75], "point": [70], "was": [71, 103, 202, 221, 246], "survival.": [73], "Secondary": [74], "points": [76], "included": [77], "progression-free": [78, 89, 171, 185, 251], "as": [80], "determined": [81], "by": [82, 289], "the": [83, 100, 111, 118, 149, 159, 206, 211, 225, 234, 243], "prostate-specific": [84], "antigen": [85], "(PSA)": [86], "level,": [87], "clinical": [88, 184], "survival,": [90], "and": [91, 114, 152, 174, 182, 188, 216, 238, 252, 277, 292, 295, 306], "adverse": [92, 200], "events.A": [93], "total": [94], "of": [95, 136, 275], "1125": [96], "underwent": [98], "randomization;": [99], "median": [101], "follow-up": [102], "34": [104], "months.": [105], "There": [106], "were": [107, 142, 166], "102": [108], "deaths": [109, 116], "group": [113, 120, 151, 208, 213, 236, 270], "143": [115], "standard-care": [119, 160, 212, 244], "(hazard": [121], "ratio,": [122, 179, 193], "0.67;": [123], "95%": [124], "confidence": [125], "interval": [126], "[CI],": [127], "0.52": [128], "0.86;": [130], "P": [131], "=": [132], "0.002).": [133], "Kaplan-Meier": [134], "estimates": [135], "at": [139], "years": [141], "80%": [143], "(based": [144, 154], "on": [145, 155], "94": [146], "events)": [147, 157], "72%": [153], "130": [156], "group.": [161], "Better": [162], "results": [163], "also": [167], "seen": [168], "PSA": [170], "(174": [173], "333": [175], "events,": [176, 190, 218], "respectively;": [177, 191], "hazard": [178, 192], "0.39;": [180], "P<0.001)": [181], "(167": [187], "320": [189], "0.40;": [194], "P<0.001).": [195], "Treatment": [196], "discontinuation": [197], "due": [198], "events": [201, 215], "more": [203, 222], "frequent": [204], "than": [209, 255], "(33": [214], "14": [217], "respectively).": [219], "Fatigue": [220], "common": [223], "group;": [227], "seizures": [228, 276], "occurred": [229], "7": [231], "(1%)": [237], "no": [240], "group.Enzalutamide": [245], "significantly": [249], "longer": [250], "care": [257], "cancer": [264], "receiving": [265], "suppression.": [267], "had": [271], "higher": [273], "incidence": [274], "other": [278], "toxic": [279], "effects,": [280], "especially": [281], "among": [282], "those": [283], "treated": [284], "docetaxel.": [287], "(Funded": [288], "Astellas": [290], "Scientific": [291], "Medical": [293], "Affairs": [294], "others;": [296], "ENZAMET": [297], "(ANZUP": [298], "1304)": [299], "ANZCTR": [300], "number,": [301, 304, 311], "ACTRN12614000110684;": [302], "ClinicalTrials.gov": [303], "NCT02446405;": [305], "EU": [307], "Clinical": [308], "Trials": [309], "Register": [310], "2014-003190-42.).": [312]}